dalteparin has been researched along with Afibrinogenemia in 3 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
Afibrinogenemia: A deficiency or absence of FIBRINOGEN in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 7.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 7.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Although congenital afibrinogenemia is a rare autosomal recessive bleeding disorder, it can be more frequently encountered in countries where consanguineous marriages are common." | 3.81 | A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations. ( Işik, B; Karakukcu, M; Mutlu, FT; Ozdemir, MA; Patiroglu, T; Unal, E; Yilmaz, E, 2015) |
| "Dysfibrinogenemia is caused by a variety of structural abnormalities in the fibrinogen molecule, which results in a tendency for bleeding and thrombosis as well as obstetric complications." | 3.75 | Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy. ( Galanakis, D; Miesbach, W; Scharrer, I, 2009) |
| "Renal infarction is a rare occurrence accounting for 0." | 1.46 | Acute renal artery infarction secondary to dysfibrinogenemia. ( Church, T; Keinath, K; Perkins, J; Sadowski, B, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keinath, K | 1 |
| Church, T | 1 |
| Sadowski, B | 1 |
| Perkins, J | 1 |
| Ozdemir, MA | 1 |
| Işik, B | 1 |
| Patiroglu, T | 1 |
| Karakukcu, M | 1 |
| Mutlu, FT | 1 |
| Yilmaz, E | 1 |
| Unal, E | 1 |
| Miesbach, W | 1 |
| Galanakis, D | 1 |
| Scharrer, I | 1 |
3 other studies available for dalteparin and Afibrinogenemia
| Article | Year |
|---|---|
Acute renal artery infarction secondary to dysfibrinogenemia.
Topics: Adult; Afibrinogenemia; Anticoagulants; Computed Tomography Angiography; Diagnosis, Differential; En | 2017 |
A case of congenital afibrinogenemia complicated with thromboembolic events that required repeated amputations.
Topics: Afibrinogenemia; Amputation, Surgical; Anemia; Anticoagulants; Blood Coagulation Tests; Disease Prog | 2015 |
Treatment of patients with dysfibrinogenemia and a history of abortions during pregnancy.
Topics: Abortion, Habitual; Abruptio Placentae; Adult; Afibrinogenemia; Enoxaparin; Female; Fibrinogen; Fibr | 2009 |